Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 10/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | TEC | P42680 | 1/20 | 0.41 |
| ▸ | TXK | P42681 | 1/20 | 0.41 |
| ▸ | BMX | P51813 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102189 | 0.92 | MPL (0.62) | MPLJAK2TYK2 | |
| SCHEMBL1102185 | 0.86 | MPL (0.84) | MPL | |
| SCHEMBL1102194 | 0.86 | MPL (0.84) | MPL | |
| SCHEMBL1102198 | 0.79 | MPL (0.60) | MPL | |
| SCHEMBL1090226 | 0.79 | MPL (0.63) | MPL | |
| SCHEMBL1091924 | 0.78 | MPL (1.00) | MPL | |
| SCHEMBL1091483 | 0.78 | MPL (0.63) | MPL | |
| Trifluoroacetic Acid SCHEMBL1091774 | 0.78 | MPL (0.64) | MPL | |
| SCHEMBL1102276 | 0.77 | MPL (1.00) | MPL | |
| SCHEMBL1102284 | 0.77 | MPL (0.58) | MPLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | MPL, TPO, THPO | MPL 1/4885MEN1 244/4885KMT2A 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.